A few of our accomplishments over our 30 year plus history: • 2008, 2007, 2006, 2005: Fortune Small Business - Fastest Growing Small Companies • 2007: Business Week 100 Hot Growth Companies • 2007: Business 2.0 100 Fastest Growing Tech Companies • 2006, 2005, 2004, 2003, 2000, 1997, 1996: Forbes Best 200 Small Companies • 2006, 2005, 2004: Meridian included in Mergent's Dividend Achievers Index due to its long history of dividend increases • 2006: Named Founding Member to new NASDAQ Dividend Achievers Index • 2006: Included in the new NASDAQ Global Select Market - The Market with the Highest Initial Listing Standards in the World • 2005: Business Week 100 Best Companies of 2005 • 2005: Red Herring Top 100 Small-Cap Companies • 2004: Meridian achieves ISO 13485 Certification • 2001: Meridian Diagnostics, Inc. becomes Meridian Bioscience, Inc. and expands into the life science industry • 1977: Meridian Diagnostics, Inc. founded Meridian was first-to-market with several key products over our history: • Rapid Shiga Toxin Test (2007) • Differentiated Shiga Toxin 1&2 (2007) • Rapid C. difficile Toxin A&B Test (2004) • E.coli O157, Direct Stool Test (2003) • H. pylori Antigen Test (1998) • Shiga Toxin Test (1995) • C. difficile Toxin A Test (1993) • Rapid C. difficile Antigen Test (1993) Meridian is the market leader in C difficile , E. coli Shiga Toxin and H. pylori Stool Antigen testing. Our broad product menu offers more than 200 products to meet our customer's needs. Our Cincinnati global headquarters houses research and development, manufacturing, warehousing, and administrative offices. Meridian employs approximately 400 people worldwide. Meridian has a long history of profitable growth. In our first full fiscal year after going public in 1986, Meridian reported revenues of $5.2 million and net earnings of $.5 million. Meridian reported results for fiscal 2008, posting sales of $139.6 million and net earnings of $30.2 million. In fiscal year 2008, sales grew 14%, and earnings grew 13%.